Basic Information
| LncRNA/CircRNA Name | UCA1 |
| Synonyms | UCA1, CUDR, LINC00178, NCRNA00178, UCAT1, onco-lncRNA-36 |
| Region | GRCh38_19:15828206-15836326 |
| Ensemble | ENSG00000214049 |
| Refseq | NR_015379 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | Artesunate | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qPCR, Western blot, RIP, Luciferase reporter assay |
| Sample | cell lines (DU145 and LNCaP) |
| Expression Pattern | up-regulated |
| Function Description | UCA1 was up-regulated in prostate cancer tissues compared to hyperplastic prostatic tissues,and a higher UCA1 level predicted poor prognosis in PCa patients.Then we determined that the miR-184/Bcl-2 axis might be the downstream signaling pathway of UCA1 upon ART treatment. UCA1 binds to miR-184 through its seed sequences and may function as a sponge for miR-184. |
| Pubmed ID | 28209917 |
| Year | 2017 |
| Title | Artesunate suppresses the viability and mobility of prostate cancer cells through UCA1, the sponge of miR-184 |
External Links
| Links for UCA1 | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |